Table 2.

Efficacy of pembrolizumab versus chemotherapy in the 3randomized clinical trials included in the analysis by TMB ≥175 mutations/exome and TMB <175 mutations/exome

Study	TMB ≥175 mutations/exome			TMB <175 mutations/exome
	ORR, OR (95% CI)	PFS, HR (95% CI)	OS, HR (95% CI)	ORR, OR (95% CI)	PFS, HR (95% CI)	OS, HR (95% CI)
KEYNOTE-010	2.82 (0.98 to 8.11)	0.59 (0.40 to 0.87)	0.56 (0.38 to 0.83)	0.76 (0.29 to 2.00)	1.09 (0.72 to 1.63)	0.85 (0.56 to 1.30)
KEYNOTE-045	3.05 (1.20 to 7.79)	0.62 (0.40 to 0.96)	0.63 (0.40 to 1.00)	1.10 (0.55 to 2.21)	1.13 (0.87 to 1.47)	0.71 (0.54 to 0.94)
KEYNOTE-061	3.43 (0.99 to 11.85)	0.73 (0.44 to 1.22)	0.46 (0.27 to 0.81)	0.61 (0.31 to 1.22)	1.78 (1.43 to 2.22)	1.12 (0.90 to 1.41)

ORR and PFS were assessed per RECIST V.1.1 by independent central review.

ORR, objective response rate; PFS, progression-free survival; TMB, tumor mutational burden.